Eli Lilly and Boehringer Ingelheim set their sights on acute heart failure with new Jardiance data
A few months after Eli Lilly and Boehringer Ingelheim broke into the chronic heart failure space with their SGLT2 inhibitor Jardiance, the partners are already …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
